nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—Cytochrome P450 2D6 Inhibitors—Pazopanib—kidney cancer	0.302	0.5	CiPCiCtD
Mirabegron—Cytochrome P450 2D6 Inhibitors—Everolimus—kidney cancer	0.302	0.5	CiPCiCtD
Mirabegron—BCHE—kidney cancer	0.123	0.719	CbGaD
Mirabegron—ABCB1—kidney cancer	0.0481	0.282	CbGaD
Mirabegron—ORM1—Erlotinib—kidney cancer	0.0225	0.137	CbGbCtD
Mirabegron—ABCB1—Temsirolimus—kidney cancer	0.0132	0.0805	CbGbCtD
Mirabegron—CYP2D6—Temsirolimus—kidney cancer	0.0124	0.0759	CbGbCtD
Mirabegron—CYP3A4—Everolimus—kidney cancer	0.0117	0.0714	CbGbCtD
Mirabegron—ALB—Erlotinib—kidney cancer	0.00945	0.0577	CbGbCtD
Mirabegron—CYP3A4—Temsirolimus—kidney cancer	0.0079	0.0482	CbGbCtD
Mirabegron—ABCB1—Pazopanib—kidney cancer	0.00693	0.0423	CbGbCtD
Mirabegron—CYP2D6—Pazopanib—kidney cancer	0.00653	0.0398	CbGbCtD
Mirabegron—ABCB1—Dactinomycin—kidney cancer	0.00634	0.0387	CbGbCtD
Mirabegron—ABCB1—Gemcitabine—kidney cancer	0.00501	0.0306	CbGbCtD
Mirabegron—ABCB1—Erlotinib—kidney cancer	0.00494	0.0302	CbGbCtD
Mirabegron—CYP2D6—Erlotinib—kidney cancer	0.00466	0.0284	CbGbCtD
Mirabegron—ABCB1—Paclitaxel—kidney cancer	0.00453	0.0276	CbGbCtD
Mirabegron—CYP3A4—Pazopanib—kidney cancer	0.00415	0.0253	CbGbCtD
Mirabegron—ABCB1—Sorafenib—kidney cancer	0.00402	0.0245	CbGbCtD
Mirabegron—ABCB1—Vinblastine—kidney cancer	0.00397	0.0242	CbGbCtD
Mirabegron—ABCB1—Vincristine—kidney cancer	0.0039	0.0238	CbGbCtD
Mirabegron—CYP2D6—Sorafenib—kidney cancer	0.00379	0.0231	CbGbCtD
Mirabegron—CYP2D6—Vinblastine—kidney cancer	0.00374	0.0228	CbGbCtD
Mirabegron—ABCB1—Sunitinib—kidney cancer	0.00326	0.0199	CbGbCtD
Mirabegron—CYP3A4—Erlotinib—kidney cancer	0.00296	0.0181	CbGbCtD
Mirabegron—CYP3A4—Paclitaxel—kidney cancer	0.00271	0.0165	CbGbCtD
Mirabegron—ABCB1—Doxorubicin—kidney cancer	0.00244	0.0149	CbGbCtD
Mirabegron—CYP3A4—Sorafenib—kidney cancer	0.00241	0.0147	CbGbCtD
Mirabegron—CYP3A4—Vinblastine—kidney cancer	0.00238	0.0145	CbGbCtD
Mirabegron—CYP3A4—Vincristine—kidney cancer	0.00234	0.0143	CbGbCtD
Mirabegron—CYP2D6—Doxorubicin—kidney cancer	0.0023	0.014	CbGbCtD
Mirabegron—CYP3A4—Sunitinib—kidney cancer	0.00195	0.0119	CbGbCtD
Mirabegron—CYP3A4—Doxorubicin—kidney cancer	0.00146	0.00892	CbGbCtD
Mirabegron—Rash—Temsirolimus—kidney cancer	8.38e-05	0.00146	CcSEcCtD
Mirabegron—Dermatitis—Temsirolimus—kidney cancer	8.37e-05	0.00146	CcSEcCtD
Mirabegron—Breast disorder—Capecitabine—kidney cancer	8.37e-05	0.00146	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Capecitabine—kidney cancer	8.34e-05	0.00145	CcSEcCtD
Mirabegron—Skin disorder—Sorafenib—kidney cancer	8.33e-05	0.00145	CcSEcCtD
Mirabegron—Headache—Temsirolimus—kidney cancer	8.33e-05	0.00145	CcSEcCtD
Mirabegron—Nasopharyngitis—Capecitabine—kidney cancer	8.28e-05	0.00144	CcSEcCtD
Mirabegron—Dizziness—Pazopanib—kidney cancer	8.28e-05	0.00144	CcSEcCtD
Mirabegron—Back pain—Vincristine—kidney cancer	8.28e-05	0.00144	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Erlotinib—kidney cancer	8.23e-05	0.00144	CcSEcCtD
Mirabegron—Fatigue—Erlotinib—kidney cancer	8.22e-05	0.00143	CcSEcCtD
Mirabegron—Infection—Sunitinib—kidney cancer	8.2e-05	0.00143	CcSEcCtD
Mirabegron—Gastritis—Capecitabine—kidney cancer	8.2e-05	0.00143	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Capecitabine—kidney cancer	8.17e-05	0.00142	CcSEcCtD
Mirabegron—Sinusitis—Paclitaxel—kidney cancer	8.16e-05	0.00142	CcSEcCtD
Mirabegron—Constipation—Erlotinib—kidney cancer	8.16e-05	0.00142	CcSEcCtD
Mirabegron—Gastrointestinal pain—Vinblastine—kidney cancer	8.11e-05	0.00142	CcSEcCtD
Mirabegron—Gastrointestinal pain—Everolimus—kidney cancer	8.08e-05	0.00141	CcSEcCtD
Mirabegron—Abdominal distension—Capecitabine—kidney cancer	8.06e-05	0.00141	CcSEcCtD
Mirabegron—Cystitis noninfective—Doxorubicin—kidney cancer	8.03e-05	0.0014	CcSEcCtD
Mirabegron—Skin disorder—Sunitinib—kidney cancer	8.02e-05	0.0014	CcSEcCtD
Mirabegron—Influenza—Capecitabine—kidney cancer	8e-05	0.0014	CcSEcCtD
Mirabegron—Cystitis—Doxorubicin—kidney cancer	7.94e-05	0.00138	CcSEcCtD
Mirabegron—Rash—Pazopanib—kidney cancer	7.89e-05	0.00138	CcSEcCtD
Mirabegron—Nausea—Temsirolimus—kidney cancer	7.89e-05	0.00138	CcSEcCtD
Mirabegron—Dermatitis—Pazopanib—kidney cancer	7.89e-05	0.00138	CcSEcCtD
Mirabegron—Back pain—Gemcitabine—kidney cancer	7.85e-05	0.00137	CcSEcCtD
Mirabegron—Abdominal pain—Vinblastine—kidney cancer	7.84e-05	0.00137	CcSEcCtD
Mirabegron—Headache—Pazopanib—kidney cancer	7.84e-05	0.00137	CcSEcCtD
Mirabegron—Rhinitis—Paclitaxel—kidney cancer	7.83e-05	0.00137	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Sorafenib—kidney cancer	7.82e-05	0.00136	CcSEcCtD
Mirabegron—Abdominal pain—Everolimus—kidney cancer	7.81e-05	0.00136	CcSEcCtD
Mirabegron—Gastrointestinal pain—Erlotinib—kidney cancer	7.8e-05	0.00136	CcSEcCtD
Mirabegron—Infection—Dactinomycin—kidney cancer	7.77e-05	0.00135	CcSEcCtD
Mirabegron—Vaginal infection—Doxorubicin—kidney cancer	7.76e-05	0.00135	CcSEcCtD
Mirabegron—Urinary tract disorder—Paclitaxel—kidney cancer	7.71e-05	0.00134	CcSEcCtD
Mirabegron—Connective tissue disorder—Paclitaxel—kidney cancer	7.67e-05	0.00134	CcSEcCtD
Mirabegron—Urethral disorder—Paclitaxel—kidney cancer	7.65e-05	0.00133	CcSEcCtD
Mirabegron—Dry eye—Doxorubicin—kidney cancer	7.6e-05	0.00132	CcSEcCtD
Mirabegron—Dyspepsia—Sorafenib—kidney cancer	7.55e-05	0.00132	CcSEcCtD
Mirabegron—Abdominal pain—Erlotinib—kidney cancer	7.54e-05	0.00131	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Sunitinib—kidney cancer	7.52e-05	0.00131	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Capecitabine—kidney cancer	7.44e-05	0.0013	CcSEcCtD
Mirabegron—Nausea—Pazopanib—kidney cancer	7.44e-05	0.0013	CcSEcCtD
Mirabegron—Neoplasm—Doxorubicin—kidney cancer	7.44e-05	0.0013	CcSEcCtD
Mirabegron—Bladder pain—Doxorubicin—kidney cancer	7.44e-05	0.0013	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Sorafenib—kidney cancer	7.41e-05	0.00129	CcSEcCtD
Mirabegron—Fatigue—Sorafenib—kidney cancer	7.4e-05	0.00129	CcSEcCtD
Mirabegron—Hypertension—Vincristine—kidney cancer	7.39e-05	0.00129	CcSEcCtD
Mirabegron—Erythema multiforme—Paclitaxel—kidney cancer	7.38e-05	0.00129	CcSEcCtD
Mirabegron—Constipation—Sorafenib—kidney cancer	7.34e-05	0.00128	CcSEcCtD
Mirabegron—Eye disorder—Paclitaxel—kidney cancer	7.3e-05	0.00127	CcSEcCtD
Mirabegron—Dyspepsia—Sunitinib—kidney cancer	7.27e-05	0.00127	CcSEcCtD
Mirabegron—Cardiac disorder—Paclitaxel—kidney cancer	7.25e-05	0.00126	CcSEcCtD
Mirabegron—Infestation NOS—Capecitabine—kidney cancer	7.14e-05	0.00124	CcSEcCtD
Mirabegron—Infestation—Capecitabine—kidney cancer	7.14e-05	0.00124	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Sunitinib—kidney cancer	7.13e-05	0.00124	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Dactinomycin—kidney cancer	7.12e-05	0.00124	CcSEcCtD
Mirabegron—Asthenia—Vinblastine—kidney cancer	7.12e-05	0.00124	CcSEcCtD
Mirabegron—Fatigue—Sunitinib—kidney cancer	7.12e-05	0.00124	CcSEcCtD
Mirabegron—Asthenia—Everolimus—kidney cancer	7.09e-05	0.00124	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Capecitabine—kidney cancer	7.08e-05	0.00123	CcSEcCtD
Mirabegron—Constipation—Sunitinib—kidney cancer	7.06e-05	0.00123	CcSEcCtD
Mirabegron—Gastrointestinal pain—Sorafenib—kidney cancer	7.02e-05	0.00122	CcSEcCtD
Mirabegron—Hypertension—Gemcitabine—kidney cancer	7.01e-05	0.00122	CcSEcCtD
Mirabegron—Pruritus—Everolimus—kidney cancer	6.99e-05	0.00122	CcSEcCtD
Mirabegron—Infection—Vincristine—kidney cancer	6.94e-05	0.00121	CcSEcCtD
Mirabegron—Urinary tract infection—Capecitabine—kidney cancer	6.94e-05	0.00121	CcSEcCtD
Mirabegron—Arthralgia—Gemcitabine—kidney cancer	6.91e-05	0.00121	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	6.86e-05	0.0012	CcSEcCtD
Mirabegron—Asthenia—Erlotinib—kidney cancer	6.84e-05	0.00119	CcSEcCtD
Mirabegron—Urticaria—Sorafenib—kidney cancer	6.82e-05	0.00119	CcSEcCtD
Mirabegron—Diarrhoea—Vinblastine—kidney cancer	6.79e-05	0.00118	CcSEcCtD
Mirabegron—Abdominal pain—Sorafenib—kidney cancer	6.78e-05	0.00118	CcSEcCtD
Mirabegron—Diarrhoea—Everolimus—kidney cancer	6.76e-05	0.00118	CcSEcCtD
Mirabegron—Gastrointestinal pain—Sunitinib—kidney cancer	6.75e-05	0.00118	CcSEcCtD
Mirabegron—Pruritus—Erlotinib—kidney cancer	6.75e-05	0.00118	CcSEcCtD
Mirabegron—Fatigue—Dactinomycin—kidney cancer	6.74e-05	0.00118	CcSEcCtD
Mirabegron—Vascular purpura—Doxorubicin—kidney cancer	6.67e-05	0.00116	CcSEcCtD
Mirabegron—Infection—Gemcitabine—kidney cancer	6.58e-05	0.00115	CcSEcCtD
Mirabegron—Back pain—Paclitaxel—kidney cancer	6.57e-05	0.00115	CcSEcCtD
Mirabegron—Dizziness—Vinblastine—kidney cancer	6.56e-05	0.00114	CcSEcCtD
Mirabegron—Dizziness—Everolimus—kidney cancer	6.54e-05	0.00114	CcSEcCtD
Mirabegron—Abdominal pain—Sunitinib—kidney cancer	6.53e-05	0.00114	CcSEcCtD
Mirabegron—Diarrhoea—Erlotinib—kidney cancer	6.53e-05	0.00114	CcSEcCtD
Mirabegron—Skin disorder—Gemcitabine—kidney cancer	6.44e-05	0.00112	CcSEcCtD
Mirabegron—Rhinitis—Capecitabine—kidney cancer	6.42e-05	0.00112	CcSEcCtD
Mirabegron—Vision blurred—Paclitaxel—kidney cancer	6.41e-05	0.00112	CcSEcCtD
Mirabegron—Gastrointestinal pain—Dactinomycin—kidney cancer	6.39e-05	0.00111	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Vincristine—kidney cancer	6.36e-05	0.00111	CcSEcCtD
Mirabegron—Urinary tract disorder—Capecitabine—kidney cancer	6.33e-05	0.0011	CcSEcCtD
Mirabegron—Dizziness—Erlotinib—kidney cancer	6.31e-05	0.0011	CcSEcCtD
Mirabegron—Connective tissue disorder—Capecitabine—kidney cancer	6.3e-05	0.0011	CcSEcCtD
Mirabegron—Urethral disorder—Capecitabine—kidney cancer	6.28e-05	0.0011	CcSEcCtD
Mirabegron—Rash—Everolimus—kidney cancer	6.23e-05	0.00109	CcSEcCtD
Mirabegron—Dermatitis—Everolimus—kidney cancer	6.23e-05	0.00109	CcSEcCtD
Mirabegron—Headache—Vinblastine—kidney cancer	6.22e-05	0.00108	CcSEcCtD
Mirabegron—Purpura—Doxorubicin—kidney cancer	6.19e-05	0.00108	CcSEcCtD
Mirabegron—Headache—Everolimus—kidney cancer	6.19e-05	0.00108	CcSEcCtD
Mirabegron—Abdominal pain—Dactinomycin—kidney cancer	6.18e-05	0.00108	CcSEcCtD
Mirabegron—Asthenia—Sorafenib—kidney cancer	6.16e-05	0.00107	CcSEcCtD
Mirabegron—Cerebrovascular accident—Doxorubicin—kidney cancer	6.09e-05	0.00106	CcSEcCtD
Mirabegron—Pruritus—Sorafenib—kidney cancer	6.07e-05	0.00106	CcSEcCtD
Mirabegron—Erythema multiforme—Capecitabine—kidney cancer	6.06e-05	0.00106	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Gemcitabine—kidney cancer	6.04e-05	0.00105	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Vincristine—kidney cancer	6.03e-05	0.00105	CcSEcCtD
Mirabegron—Fatigue—Vincristine—kidney cancer	6.02e-05	0.00105	CcSEcCtD
Mirabegron—Rash—Erlotinib—kidney cancer	6.01e-05	0.00105	CcSEcCtD
Mirabegron—Dermatitis—Erlotinib—kidney cancer	6.01e-05	0.00105	CcSEcCtD
Mirabegron—Palpitations—Paclitaxel—kidney cancer	6.01e-05	0.00105	CcSEcCtD
Mirabegron—Eye disorder—Capecitabine—kidney cancer	5.99e-05	0.00104	CcSEcCtD
Mirabegron—Headache—Erlotinib—kidney cancer	5.98e-05	0.00104	CcSEcCtD
Mirabegron—Constipation—Vincristine—kidney cancer	5.97e-05	0.00104	CcSEcCtD
Mirabegron—Osteoarthritis—Doxorubicin—kidney cancer	5.97e-05	0.00104	CcSEcCtD
Mirabegron—Cardiac disorder—Capecitabine—kidney cancer	5.95e-05	0.00104	CcSEcCtD
Mirabegron—Asthenia—Sunitinib—kidney cancer	5.92e-05	0.00103	CcSEcCtD
Mirabegron—Nausea—Vinblastine—kidney cancer	5.89e-05	0.00103	CcSEcCtD
Mirabegron—Nausea—Everolimus—kidney cancer	5.87e-05	0.00102	CcSEcCtD
Mirabegron—Diarrhoea—Sorafenib—kidney cancer	5.87e-05	0.00102	CcSEcCtD
Mirabegron—Hypertension—Paclitaxel—kidney cancer	5.87e-05	0.00102	CcSEcCtD
Mirabegron—Pruritus—Sunitinib—kidney cancer	5.84e-05	0.00102	CcSEcCtD
Mirabegron—Arthralgia—Paclitaxel—kidney cancer	5.79e-05	0.00101	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	5.75e-05	0.001	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Gemcitabine—kidney cancer	5.72e-05	0.000997	CcSEcCtD
Mirabegron—Fatigue—Gemcitabine—kidney cancer	5.71e-05	0.000996	CcSEcCtD
Mirabegron—Gastrointestinal pain—Vincristine—kidney cancer	5.71e-05	0.000996	CcSEcCtD
Mirabegron—Dizziness—Sorafenib—kidney cancer	5.67e-05	0.00099	CcSEcCtD
Mirabegron—Constipation—Gemcitabine—kidney cancer	5.67e-05	0.000988	CcSEcCtD
Mirabegron—Nausea—Erlotinib—kidney cancer	5.67e-05	0.000988	CcSEcCtD
Mirabegron—Dry mouth—Paclitaxel—kidney cancer	5.66e-05	0.000987	CcSEcCtD
Mirabegron—Diarrhoea—Sunitinib—kidney cancer	5.65e-05	0.000985	CcSEcCtD
Mirabegron—Asthenia—Dactinomycin—kidney cancer	5.61e-05	0.000978	CcSEcCtD
Mirabegron—Abdominal pain—Vincristine—kidney cancer	5.52e-05	0.000963	CcSEcCtD
Mirabegron—Infection—Paclitaxel—kidney cancer	5.51e-05	0.000961	CcSEcCtD
Mirabegron—Dizziness—Sunitinib—kidney cancer	5.46e-05	0.000952	CcSEcCtD
Mirabegron—Tachycardia—Paclitaxel—kidney cancer	5.41e-05	0.000944	CcSEcCtD
Mirabegron—Rash—Sorafenib—kidney cancer	5.41e-05	0.000944	CcSEcCtD
Mirabegron—Dermatitis—Sorafenib—kidney cancer	5.41e-05	0.000943	CcSEcCtD
Mirabegron—Back pain—Capecitabine—kidney cancer	5.4e-05	0.000941	CcSEcCtD
Mirabegron—Breast disorder—Doxorubicin—kidney cancer	5.39e-05	0.000941	CcSEcCtD
Mirabegron—Skin disorder—Paclitaxel—kidney cancer	5.39e-05	0.00094	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	5.38e-05	0.000938	CcSEcCtD
Mirabegron—Headache—Sorafenib—kidney cancer	5.38e-05	0.000937	CcSEcCtD
Mirabegron—Diarrhoea—Dactinomycin—kidney cancer	5.35e-05	0.000933	CcSEcCtD
Mirabegron—Nasopharyngitis—Doxorubicin—kidney cancer	5.34e-05	0.000931	CcSEcCtD
Mirabegron—Gastritis—Doxorubicin—kidney cancer	5.28e-05	0.000921	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Doxorubicin—kidney cancer	5.27e-05	0.000918	CcSEcCtD
Mirabegron—Vision blurred—Capecitabine—kidney cancer	5.26e-05	0.000917	CcSEcCtD
Mirabegron—Rash—Sunitinib—kidney cancer	5.21e-05	0.000908	CcSEcCtD
Mirabegron—Dermatitis—Sunitinib—kidney cancer	5.2e-05	0.000907	CcSEcCtD
Mirabegron—Abdominal distension—Doxorubicin—kidney cancer	5.19e-05	0.000906	CcSEcCtD
Mirabegron—Headache—Sunitinib—kidney cancer	5.17e-05	0.000902	CcSEcCtD
Mirabegron—Influenza—Doxorubicin—kidney cancer	5.16e-05	0.0009	CcSEcCtD
Mirabegron—Nausea—Sorafenib—kidney cancer	5.1e-05	0.000889	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Paclitaxel—kidney cancer	5.05e-05	0.000881	CcSEcCtD
Mirabegron—Asthenia—Vincristine—kidney cancer	5.01e-05	0.000874	CcSEcCtD
Mirabegron—Palpitations—Capecitabine—kidney cancer	4.93e-05	0.00086	CcSEcCtD
Mirabegron—Rash—Dactinomycin—kidney cancer	4.93e-05	0.00086	CcSEcCtD
Mirabegron—Nausea—Sunitinib—kidney cancer	4.9e-05	0.000855	CcSEcCtD
Mirabegron—Dyspepsia—Paclitaxel—kidney cancer	4.88e-05	0.000852	CcSEcCtD
Mirabegron—Hypertension—Capecitabine—kidney cancer	4.82e-05	0.00084	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Doxorubicin—kidney cancer	4.8e-05	0.000836	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Paclitaxel—kidney cancer	4.79e-05	0.000835	CcSEcCtD
Mirabegron—Fatigue—Paclitaxel—kidney cancer	4.78e-05	0.000834	CcSEcCtD
Mirabegron—Diarrhoea—Vincristine—kidney cancer	4.78e-05	0.000833	CcSEcCtD
Mirabegron—Asthenia—Gemcitabine—kidney cancer	4.75e-05	0.000829	CcSEcCtD
Mirabegron—Arthralgia—Capecitabine—kidney cancer	4.75e-05	0.000828	CcSEcCtD
Mirabegron—Constipation—Paclitaxel—kidney cancer	4.74e-05	0.000827	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	4.72e-05	0.000822	CcSEcCtD
Mirabegron—Pruritus—Gemcitabine—kidney cancer	4.69e-05	0.000817	CcSEcCtD
Mirabegron—Dry mouth—Capecitabine—kidney cancer	4.64e-05	0.00081	CcSEcCtD
Mirabegron—Nausea—Dactinomycin—kidney cancer	4.64e-05	0.00081	CcSEcCtD
Mirabegron—Dizziness—Vincristine—kidney cancer	4.62e-05	0.000805	CcSEcCtD
Mirabegron—Infestation NOS—Doxorubicin—kidney cancer	4.6e-05	0.000802	CcSEcCtD
Mirabegron—Infestation—Doxorubicin—kidney cancer	4.6e-05	0.000802	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	4.56e-05	0.000795	CcSEcCtD
Mirabegron—Gastrointestinal pain—Paclitaxel—kidney cancer	4.54e-05	0.000791	CcSEcCtD
Mirabegron—Diarrhoea—Gemcitabine—kidney cancer	4.53e-05	0.000791	CcSEcCtD
Mirabegron—Infection—Capecitabine—kidney cancer	4.52e-05	0.000789	CcSEcCtD
Mirabegron—Urinary tract infection—Doxorubicin—kidney cancer	4.47e-05	0.00078	CcSEcCtD
Mirabegron—Tachycardia—Capecitabine—kidney cancer	4.44e-05	0.000775	CcSEcCtD
Mirabegron—Skin disorder—Capecitabine—kidney cancer	4.42e-05	0.000771	CcSEcCtD
Mirabegron—Urticaria—Paclitaxel—kidney cancer	4.41e-05	0.000768	CcSEcCtD
Mirabegron—Rash—Vincristine—kidney cancer	4.4e-05	0.000768	CcSEcCtD
Mirabegron—Dermatitis—Vincristine—kidney cancer	4.4e-05	0.000767	CcSEcCtD
Mirabegron—Abdominal pain—Paclitaxel—kidney cancer	4.38e-05	0.000765	CcSEcCtD
Mirabegron—Headache—Vincristine—kidney cancer	4.37e-05	0.000763	CcSEcCtD
Mirabegron—Sinusitis—Doxorubicin—kidney cancer	4.32e-05	0.000753	CcSEcCtD
Mirabegron—Rash—Gemcitabine—kidney cancer	4.18e-05	0.000728	CcSEcCtD
Mirabegron—Dermatitis—Gemcitabine—kidney cancer	4.17e-05	0.000728	CcSEcCtD
Mirabegron—Headache—Gemcitabine—kidney cancer	4.15e-05	0.000724	CcSEcCtD
Mirabegron—Nausea—Vincristine—kidney cancer	4.15e-05	0.000723	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Capecitabine—kidney cancer	4.15e-05	0.000723	CcSEcCtD
Mirabegron—Rhinitis—Doxorubicin—kidney cancer	4.14e-05	0.000722	CcSEcCtD
Mirabegron—Urinary tract disorder—Doxorubicin—kidney cancer	4.08e-05	0.000711	CcSEcCtD
Mirabegron—Connective tissue disorder—Doxorubicin—kidney cancer	4.06e-05	0.000708	CcSEcCtD
Mirabegron—Urethral disorder—Doxorubicin—kidney cancer	4.05e-05	0.000706	CcSEcCtD
Mirabegron—Dyspepsia—Capecitabine—kidney cancer	4.01e-05	0.000699	CcSEcCtD
Mirabegron—Asthenia—Paclitaxel—kidney cancer	3.98e-05	0.000694	CcSEcCtD
Mirabegron—Nausea—Gemcitabine—kidney cancer	3.94e-05	0.000686	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Capecitabine—kidney cancer	3.93e-05	0.000685	CcSEcCtD
Mirabegron—Fatigue—Capecitabine—kidney cancer	3.92e-05	0.000684	CcSEcCtD
Mirabegron—Pruritus—Paclitaxel—kidney cancer	3.92e-05	0.000684	CcSEcCtD
Mirabegron—Erythema multiforme—Doxorubicin—kidney cancer	3.9e-05	0.000681	CcSEcCtD
Mirabegron—Constipation—Capecitabine—kidney cancer	3.89e-05	0.000679	CcSEcCtD
Mirabegron—Eye disorder—Doxorubicin—kidney cancer	3.86e-05	0.000673	CcSEcCtD
Mirabegron—Cardiac disorder—Doxorubicin—kidney cancer	3.83e-05	0.000668	CcSEcCtD
Mirabegron—Diarrhoea—Paclitaxel—kidney cancer	3.8e-05	0.000662	CcSEcCtD
Mirabegron—Gastrointestinal pain—Capecitabine—kidney cancer	3.72e-05	0.000649	CcSEcCtD
Mirabegron—Dizziness—Paclitaxel—kidney cancer	3.67e-05	0.00064	CcSEcCtD
Mirabegron—Urticaria—Capecitabine—kidney cancer	3.62e-05	0.000631	CcSEcCtD
Mirabegron—Abdominal pain—Capecitabine—kidney cancer	3.6e-05	0.000628	CcSEcCtD
Mirabegron—Rash—Paclitaxel—kidney cancer	3.5e-05	0.00061	CcSEcCtD
Mirabegron—Dermatitis—Paclitaxel—kidney cancer	3.49e-05	0.000609	CcSEcCtD
Mirabegron—Back pain—Doxorubicin—kidney cancer	3.48e-05	0.000606	CcSEcCtD
Mirabegron—Headache—Paclitaxel—kidney cancer	3.47e-05	0.000606	CcSEcCtD
Mirabegron—Vision blurred—Doxorubicin—kidney cancer	3.39e-05	0.000591	CcSEcCtD
Mirabegron—Nausea—Paclitaxel—kidney cancer	3.29e-05	0.000575	CcSEcCtD
Mirabegron—Asthenia—Capecitabine—kidney cancer	3.27e-05	0.00057	CcSEcCtD
Mirabegron—Pruritus—Capecitabine—kidney cancer	3.22e-05	0.000562	CcSEcCtD
Mirabegron—Palpitations—Doxorubicin—kidney cancer	3.18e-05	0.000554	CcSEcCtD
Mirabegron—Diarrhoea—Capecitabine—kidney cancer	3.11e-05	0.000543	CcSEcCtD
Mirabegron—Hypertension—Doxorubicin—kidney cancer	3.1e-05	0.000541	CcSEcCtD
Mirabegron—Arthralgia—Doxorubicin—kidney cancer	3.06e-05	0.000534	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	3.04e-05	0.00053	CcSEcCtD
Mirabegron—Dizziness—Capecitabine—kidney cancer	3.01e-05	0.000525	CcSEcCtD
Mirabegron—Dry mouth—Doxorubicin—kidney cancer	2.99e-05	0.000522	CcSEcCtD
Mirabegron—Infection—Doxorubicin—kidney cancer	2.92e-05	0.000508	CcSEcCtD
Mirabegron—Rash—Capecitabine—kidney cancer	2.87e-05	0.000501	CcSEcCtD
Mirabegron—Dermatitis—Capecitabine—kidney cancer	2.87e-05	0.0005	CcSEcCtD
Mirabegron—Tachycardia—Doxorubicin—kidney cancer	2.86e-05	0.000499	CcSEcCtD
Mirabegron—Headache—Capecitabine—kidney cancer	2.85e-05	0.000497	CcSEcCtD
Mirabegron—Skin disorder—Doxorubicin—kidney cancer	2.85e-05	0.000497	CcSEcCtD
Mirabegron—Nausea—Capecitabine—kidney cancer	2.7e-05	0.000472	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.67e-05	0.000466	CcSEcCtD
Mirabegron—Dyspepsia—Doxorubicin—kidney cancer	2.58e-05	0.00045	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.53e-05	0.000442	CcSEcCtD
Mirabegron—Fatigue—Doxorubicin—kidney cancer	2.53e-05	0.000441	CcSEcCtD
Mirabegron—Constipation—Doxorubicin—kidney cancer	2.51e-05	0.000438	CcSEcCtD
Mirabegron—Gastrointestinal pain—Doxorubicin—kidney cancer	2.4e-05	0.000418	CcSEcCtD
Mirabegron—Urticaria—Doxorubicin—kidney cancer	2.33e-05	0.000407	CcSEcCtD
Mirabegron—Abdominal pain—Doxorubicin—kidney cancer	2.32e-05	0.000405	CcSEcCtD
Mirabegron—Asthenia—Doxorubicin—kidney cancer	2.11e-05	0.000367	CcSEcCtD
Mirabegron—Pruritus—Doxorubicin—kidney cancer	2.08e-05	0.000362	CcSEcCtD
Mirabegron—Diarrhoea—Doxorubicin—kidney cancer	2.01e-05	0.00035	CcSEcCtD
Mirabegron—Dizziness—Doxorubicin—kidney cancer	1.94e-05	0.000338	CcSEcCtD
Mirabegron—Rash—Doxorubicin—kidney cancer	1.85e-05	0.000323	CcSEcCtD
Mirabegron—Dermatitis—Doxorubicin—kidney cancer	1.85e-05	0.000322	CcSEcCtD
Mirabegron—Headache—Doxorubicin—kidney cancer	1.84e-05	0.000321	CcSEcCtD
Mirabegron—Nausea—Doxorubicin—kidney cancer	1.74e-05	0.000304	CcSEcCtD
Mirabegron—ALB—Hemostasis—IFNA1—kidney cancer	3.14e-06	0.000782	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	3.13e-06	0.000781	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ITPR2—kidney cancer	3.11e-06	0.000776	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—JUNB—kidney cancer	3.1e-06	0.000772	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PAK1—kidney cancer	3.1e-06	0.000772	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	3.09e-06	0.00077	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—SCARB1—kidney cancer	3.06e-06	0.000763	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTGS1—kidney cancer	3.03e-06	0.000755	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	3.01e-06	0.000751	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GLIPR1—kidney cancer	2.98e-06	0.000743	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PPAT—kidney cancer	2.98e-06	0.000743	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GPC3—kidney cancer	2.97e-06	0.000741	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PSMD7—kidney cancer	2.97e-06	0.000741	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	2.97e-06	0.00074	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IFNA2—kidney cancer	2.92e-06	0.000728	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.9e-06	0.000724	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CA2—kidney cancer	2.89e-06	0.000721	CbGpPWpGaD
Mirabegron—BCHE—Neuronal System—MAPK1—kidney cancer	2.87e-06	0.000715	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.87e-06	0.000715	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—POMC—kidney cancer	2.86e-06	0.000713	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GSTT1—kidney cancer	2.84e-06	0.000707	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ACHE—kidney cancer	2.84e-06	0.000707	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ALAD—kidney cancer	2.82e-06	0.000703	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—BCHE—kidney cancer	2.82e-06	0.000702	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GLIPR1—kidney cancer	2.81e-06	0.0007	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PPAT—kidney cancer	2.81e-06	0.0007	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—RAF1—kidney cancer	2.81e-06	0.0007	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.8e-06	0.000699	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—SLC5A5—kidney cancer	2.78e-06	0.000694	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—APRT—kidney cancer	2.77e-06	0.000691	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—FH—kidney cancer	2.77e-06	0.000691	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	2.76e-06	0.000689	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ST3GAL2—kidney cancer	2.75e-06	0.000686	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	2.73e-06	0.000682	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ALDH1A1—kidney cancer	2.69e-06	0.00067	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—SLC2A1—kidney cancer	2.69e-06	0.00067	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—SCARB1—kidney cancer	2.69e-06	0.00067	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	2.67e-06	0.000666	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTGS1—kidney cancer	2.66e-06	0.000663	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ACY1—kidney cancer	2.65e-06	0.00066	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IGF2—kidney cancer	2.63e-06	0.000655	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—FH—kidney cancer	2.61e-06	0.000651	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—APRT—kidney cancer	2.61e-06	0.000651	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.61e-06	0.00065	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PSMD7—kidney cancer	2.61e-06	0.00065	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GPC3—kidney cancer	2.61e-06	0.000649	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PGK1—kidney cancer	2.58e-06	0.000643	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SLC5A3—kidney cancer	2.58e-06	0.000643	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—RAF1—kidney cancer	2.56e-06	0.000639	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	2.54e-06	0.000634	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CA2—kidney cancer	2.53e-06	0.000632	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	2.53e-06	0.000631	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IGF2—kidney cancer	2.53e-06	0.000631	CbGpPWpGaD
Mirabegron—ALB—Metabolism—LDHB—kidney cancer	2.53e-06	0.00063	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CDKN2B—kidney cancer	2.52e-06	0.000628	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—IL2—kidney cancer	2.52e-06	0.000627	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—POMC—kidney cancer	2.48e-06	0.000618	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ALAD—kidney cancer	2.47e-06	0.000616	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	2.46e-06	0.000612	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GPC3—kidney cancer	2.46e-06	0.000612	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IGF1R—kidney cancer	2.45e-06	0.00061	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—SLC5A5—kidney cancer	2.44e-06	0.000609	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	2.42e-06	0.000602	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ST3GAL2—kidney cancer	2.41e-06	0.000601	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	2.41e-06	0.000601	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	2.39e-06	0.000596	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CA2—kidney cancer	2.39e-06	0.000595	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—SLC2A1—kidney cancer	2.36e-06	0.000588	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—RAF1—kidney cancer	2.36e-06	0.000588	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ALDH1A1—kidney cancer	2.36e-06	0.000587	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	2.33e-06	0.000581	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—IL2—kidney cancer	2.33e-06	0.00058	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ALAD—kidney cancer	2.33e-06	0.00058	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.29e-06	0.00057	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.27e-06	0.000567	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ST3GAL2—kidney cancer	2.27e-06	0.000566	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PGK1—kidney cancer	2.26e-06	0.000563	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SLC5A3—kidney cancer	2.26e-06	0.000563	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PDHB—kidney cancer	2.25e-06	0.000562	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—POMC—kidney cancer	2.25e-06	0.00056	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GSTP1—kidney cancer	2.24e-06	0.000559	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ALDH1A1—kidney cancer	2.22e-06	0.000553	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—LDHB—kidney cancer	2.22e-06	0.000552	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—ABCB1—kidney cancer	2.21e-06	0.000552	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CA9—kidney cancer	2.19e-06	0.000546	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.14e-06	0.000534	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	2.14e-06	0.000533	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PGK1—kidney cancer	2.13e-06	0.000531	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SLC5A3—kidney cancer	2.13e-06	0.000531	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—ABCB1—kidney cancer	2.12e-06	0.000529	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CCBL1—kidney cancer	2.12e-06	0.000528	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—IL2—kidney cancer	2.11e-06	0.000527	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	2.11e-06	0.000525	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—LDHB—kidney cancer	2.09e-06	0.00052	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GSTM1—kidney cancer	2.06e-06	0.000513	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	2.02e-06	0.000504	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—HIF1A—kidney cancer	2.01e-06	0.000502	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TSC2—kidney cancer	2.01e-06	0.000501	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2e-06	0.000497	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.99e-06	0.000497	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GSTP1—kidney cancer	1.97e-06	0.00049	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CYP1A1—kidney cancer	1.95e-06	0.000487	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.94e-06	0.000483	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KDR—kidney cancer	1.93e-06	0.00048	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	1.93e-06	0.00048	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CA9—kidney cancer	1.92e-06	0.000479	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.9e-06	0.000472	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CRABP1—kidney cancer	1.86e-06	0.000465	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ABCB1—kidney cancer	1.86e-06	0.000464	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.84e-06	0.000458	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PPAT—kidney cancer	1.84e-06	0.000458	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CA9—kidney cancer	1.81e-06	0.000451	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GSTM1—kidney cancer	1.81e-06	0.000451	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.79e-06	0.000446	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—APC—kidney cancer	1.77e-06	0.000442	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KIT—kidney cancer	1.77e-06	0.000442	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—CTNNB1—kidney cancer	1.77e-06	0.000441	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ITPR2—kidney cancer	1.73e-06	0.000432	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CYP1A1—kidney cancer	1.71e-06	0.000427	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—FH—kidney cancer	1.71e-06	0.000426	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—APRT—kidney cancer	1.71e-06	0.000426	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—MAPK3—kidney cancer	1.7e-06	0.000424	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—POMC—kidney cancer	1.69e-06	0.000421	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	1.67e-06	0.000416	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—BRAF—kidney cancer	1.67e-06	0.000416	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.65e-06	0.00041	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CRABP1—kidney cancer	1.63e-06	0.000407	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—MAPK1—kidney cancer	1.62e-06	0.000403	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GPC3—kidney cancer	1.61e-06	0.0004	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.6e-06	0.0004	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.6e-06	0.000398	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.59e-06	0.000397	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTT1—kidney cancer	1.58e-06	0.000394	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ACHE—kidney cancer	1.58e-06	0.000394	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CA2—kidney cancer	1.56e-06	0.000389	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—PIK3CA—kidney cancer	1.55e-06	0.000385	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CRABP1—kidney cancer	1.54e-06	0.000384	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—KRAS—kidney cancer	1.53e-06	0.000381	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ALAD—kidney cancer	1.52e-06	0.000379	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ITPR2—kidney cancer	1.52e-06	0.000378	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SCARB1—kidney cancer	1.5e-06	0.000373	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.49e-06	0.00037	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTGS1—kidney cancer	1.48e-06	0.000369	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—POMC—kidney cancer	1.46e-06	0.000363	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PSMD7—kidney cancer	1.45e-06	0.000362	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.45e-06	0.000362	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—RAF1—kidney cancer	1.45e-06	0.000361	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ITPR2—kidney cancer	1.43e-06	0.000357	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.41e-06	0.000351	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—PIK3CA—kidney cancer	1.4e-06	0.00035	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—RAF1—kidney cancer	1.39e-06	0.000347	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.39e-06	0.000347	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PGK1—kidney cancer	1.39e-06	0.000347	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—RELA—kidney cancer	1.39e-06	0.000346	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ACHE—kidney cancer	1.38e-06	0.000345	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTT1—kidney cancer	1.38e-06	0.000345	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—ERBB2—kidney cancer	1.38e-06	0.000343	CbGpPWpGaD
Mirabegron—ALB—Metabolism—BCHE—kidney cancer	1.38e-06	0.000343	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—LDHB—kidney cancer	1.37e-06	0.00034	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MTOR—kidney cancer	1.36e-06	0.000339	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SLC5A5—kidney cancer	1.36e-06	0.000339	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SLC2A1—kidney cancer	1.31e-06	0.000327	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SCARB1—kidney cancer	1.31e-06	0.000327	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ACHE—kidney cancer	1.3e-06	0.000325	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTT1—kidney cancer	1.3e-06	0.000325	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTGS1—kidney cancer	1.3e-06	0.000323	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IL2—kidney cancer	1.3e-06	0.000323	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—POMC—kidney cancer	1.28e-06	0.000318	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CDKN1B—kidney cancer	1.28e-06	0.000318	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.27e-06	0.000318	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PSMD7—kidney cancer	1.27e-06	0.000317	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	1.25e-06	0.000312	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL2—kidney cancer	1.25e-06	0.000311	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SCARB1—kidney cancer	1.24e-06	0.000308	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTGS1—kidney cancer	1.22e-06	0.000305	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCND1—kidney cancer	1.22e-06	0.000303	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—JUN—kidney cancer	1.22e-06	0.000303	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—BCHE—kidney cancer	1.21e-06	0.000301	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CTNNB1—kidney cancer	1.21e-06	0.000301	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PSMD7—kidney cancer	1.2e-06	0.000299	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SLC5A5—kidney cancer	1.19e-06	0.000297	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CA9—kidney cancer	1.18e-06	0.000295	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTEN—kidney cancer	1.18e-06	0.000293	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTGS2—kidney cancer	1.16e-06	0.000289	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SLC2A1—kidney cancer	1.15e-06	0.000287	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—BCHE—kidney cancer	1.14e-06	0.000283	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.12e-06	0.00028	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.11e-06	0.000277	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—VEGFA—kidney cancer	1.1e-06	0.000275	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	1.1e-06	0.000274	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTP1—kidney cancer	1.1e-06	0.000273	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.08e-06	0.00027	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—VEGFA—kidney cancer	1.06e-06	0.000265	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—MAPK3—kidney cancer	1.04e-06	0.00026	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ABCB1—kidney cancer	1.04e-06	0.000258	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTGS2—kidney cancer	1.02e-06	0.000254	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTEN—kidney cancer	1.01e-06	0.000252	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTM1—kidney cancer	1.01e-06	0.000251	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CRABP1—kidney cancer	1.01e-06	0.000251	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MAPK3—kidney cancer	1e-06	0.00025	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—MAPK1—kidney cancer	9.92e-07	0.000247	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MYC—kidney cancer	9.77e-07	0.000243	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTP1—kidney cancer	9.6e-07	0.000239	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MAPK1—kidney cancer	9.55e-07	0.000238	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP1A1—kidney cancer	9.54e-07	0.000238	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—KRAS—kidney cancer	9.37e-07	0.000234	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ITPR2—kidney cancer	9.36e-07	0.000233	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTP1—kidney cancer	9.05e-07	0.000225	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KRAS—kidney cancer	9.02e-07	0.000225	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTEN—kidney cancer	8.89e-07	0.000222	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTM1—kidney cancer	8.82e-07	0.00022	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PIK3CA—kidney cancer	8.61e-07	0.000215	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ABCB1—kidney cancer	8.56e-07	0.000213	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ACHE—kidney cancer	8.53e-07	0.000213	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTT1—kidney cancer	8.53e-07	0.000213	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP1A1—kidney cancer	8.36e-07	0.000208	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TP53—kidney cancer	8.33e-07	0.000208	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTM1—kidney cancer	8.31e-07	0.000207	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PIK3CA—kidney cancer	8.29e-07	0.000207	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SCARB1—kidney cancer	8.08e-07	0.000201	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TP53—kidney cancer	8.02e-07	0.0002	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTGS1—kidney cancer	7.99e-07	0.000199	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP1A1—kidney cancer	7.88e-07	0.000196	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.84e-07	0.000195	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PSMD7—kidney cancer	7.84e-07	0.000195	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—BCHE—kidney cancer	7.43e-07	0.000185	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC5A5—kidney cancer	7.34e-07	0.000183	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PIK3CA—kidney cancer	7.15e-07	0.000178	CbGpPWpGaD
Mirabegron—ALB—Metabolism—POMC—kidney cancer	7.12e-07	0.000177	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC2A1—kidney cancer	7.09e-07	0.000177	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PIK3CA—kidney cancer	6.27e-07	0.000156	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—POMC—kidney cancer	6.23e-07	0.000155	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTP1—kidney cancer	5.91e-07	0.000147	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—POMC—kidney cancer	5.88e-07	0.000146	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTGS2—kidney cancer	5.68e-07	0.000141	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ABCB1—kidney cancer	5.6e-07	0.00014	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTM1—kidney cancer	5.43e-07	0.000135	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP1A1—kidney cancer	5.15e-07	0.000128	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTGS2—kidney cancer	4.97e-07	0.000124	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTEN—kidney cancer	4.95e-07	0.000123	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTGS2—kidney cancer	4.69e-07	0.000117	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTEN—kidney cancer	4.34e-07	0.000108	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTEN—kidney cancer	4.09e-07	0.000102	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—POMC—kidney cancer	3.84e-07	9.57e-05	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PIK3CA—kidney cancer	3.49e-07	8.7e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTGS2—kidney cancer	3.06e-07	7.64e-05	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PIK3CA—kidney cancer	3.06e-07	7.62e-05	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.88e-07	7.18e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTEN—kidney cancer	2.67e-07	6.66e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.88e-07	4.7e-05	CbGpPWpGaD
